Literature DB >> 19279169

Characterization of protective mucosal and systemic immune responses elicited by pneumococcal surface protein PspA and PspC nasal vaccines against a respiratory pneumococcal challenge in mice.

D M Ferreira1, M Darrieux, D A Silva, L C C Leite, J M C Ferreira, P L Ho, E N Miyaji, M L S Oliveira.   

Abstract

Pneumococcal surface protein A (PspA) and PspC are virulence factors that are involved in the adhesion of Streptococcus pneumoniae to epithelial cells and/or evasion from the immune system. Here, the immune responses induced by mucosal vaccines composed of both antigens as recombinant proteins or delivered by Lactobacillus casei were evaluated. None of the PspC vaccines protected mice against an invasive challenge with pneumococcal strain ATCC 6303. On the other hand, protection was observed for immunization with vaccines composed of PspA from clade 5 (PspA5 or L. casei expressing PspA5) through the intranasal route. The protective response was distinguished by a Th1 profile with high levels of immunoglobulin G2a production, efficient complement deposition, release of proinflammatory cytokines, and infiltration of neutrophils. Intranasal immunization with PspA5 elicited the highest level of protection, characterized by increased levels of secretion of interleukin-17 and gamma interferon by lung and spleen cells, respectively, and low levels of tumor necrosis factor alpha in the respiratory tract.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19279169      PMCID: PMC2681601          DOI: 10.1128/CVI.00395-08

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  54 in total

1.  Both innate immunity and type 1 humoral immunity to Streptococcus pneumoniae are mediated by MyD88 but differ in their relative levels of dependence on toll-like receptor 2.

Authors:  Abdul Q Khan; Quanyi Chen; Zheng-Qi Wu; James C Paton; Clifford M Snapper
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

2.  CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization.

Authors:  Richard Malley; Krzysztof Trzcinski; Amit Srivastava; Claudette M Thompson; Porter W Anderson; Marc Lipsitch
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-21       Impact factor: 11.205

3.  Lactobacilli activate human dendritic cells that skew T cells toward T helper 1 polarization.

Authors:  Mansour Mohamadzadeh; Scott Olson; Warren V Kalina; Gordon Ruthel; Gretchen L Demmin; Kelly L Warfield; Sina Bavari; Todd R Klaenhammer
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-14       Impact factor: 11.205

4.  WHO meeting on maternal and neonatal pneumococcal immunization.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  1998-06-19

5.  Removal of endotoxin from protein solutions by phase separation using Triton X-114.

Authors:  Y Aida; M J Pabst
Journal:  J Immunol Methods       Date:  1990-09-14       Impact factor: 2.303

6.  An assessment of the factors contributing to the killing of type 3 Streptococcus pneumoniae by human polymorphonuclear leukocytes in vitro.

Authors:  A L Esposito; C A Clark; W J Poirier
Journal:  APMIS       Date:  1990-02       Impact factor: 3.205

Review 7.  Susceptibility and resistance to pneumococcal disease in mice.

Authors:  Aras Kadioglu; Peter W Andrew
Journal:  Brief Funct Genomic Proteomic       Date:  2005-11

8.  Identification of a detrimental role for NK cells in pneumococcal pneumonia and sepsis in immunocompromised hosts.

Authors:  Alison R Kerr; Lea Ann S Kirkham; Aras Kadioglu; Peter W Andrew; Paul Garside; Hal Thompson; Tim J Mitchell
Journal:  Microbes Infect       Date:  2005-04-15       Impact factor: 2.700

9.  Essential role for the p40 subunit of interleukin-12 in neutrophil-mediated early host defense against pulmonary infection with Streptococcus pneumoniae: involvement of interferon-gamma.

Authors:  Natsuo Yamamoto; Kazuyoshi Kawakami; Yuki Kinjo; Kazuya Miyagi; Takeshi Kinjo; Kaori Uezu; Chikara Nakasone; Masashi Nakamatsu; Atsushi Saito
Journal:  Microbes Infect       Date:  2004-11       Impact factor: 2.700

10.  Antibody-independent, interleukin-17A-mediated, cross-serotype immunity to pneumococci in mice immunized intranasally with the cell wall polysaccharide.

Authors:  Richard Malley; Amit Srivastava; Marc Lipsitch; Claudette M Thompson; Claire Watkins; Arthur Tzianabos; Porter W Anderson
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

View more
  48 in total

1.  Mucosal and systemic immune responses induced by recombinant Lactobacillus spp. expressing the hemagglutinin of the avian influenza virus H5N1.

Authors:  Zhisheng Wang; Qinghua Yu; Junkai Gao; Qian Yang
Journal:  Clin Vaccine Immunol       Date:  2011-11-30

2.  Immunization with pneumolysin protects against both retinal and global damage caused by Streptococcus pneumoniae endophthalmitis.

Authors:  Melissa E Sanders; Erin W Norcross; Quincy C Moore; Jonathan Fratkin; Hilary Thompson; Mary E Marquart
Journal:  J Ocul Pharmacol Ther       Date:  2010-10-29       Impact factor: 2.671

3.  Aggregation of Streptococcus pneumoniae by a pneumococcal capsular polysaccharide-specific human monoclonal IgM correlates with antibody efficacy in vivo.

Authors:  Kevin Fabrizio; Catherine Manix; Allan J Guimaraes; Joshua D Nosanchuk; Liise-Anne Pirofski
Journal:  Clin Vaccine Immunol       Date:  2010-03-03

Review 4.  Pathogenesis and pathophysiology of pneumococcal meningitis.

Authors:  Barry B Mook-Kanamori; Madelijn Geldhoff; Tom van der Poll; Diederik van de Beek
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

5.  A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA).

Authors:  Kristopher R Genschmer; Mary Ann Accavitti-Loper; David E Briles
Journal:  Vaccine       Date:  2013-11-06       Impact factor: 3.641

6.  Maternal antibodies to pneumolysin but not to pneumococcal surface protein A delay early pneumococcal carriage in high-risk Papua New Guinean infants.

Authors:  Jacinta P Francis; Peter C Richmond; William S Pomat; Audrey Michael; Helen Keno; Suparat Phuanukoonnon; Jan B Nelson; Melissa Whinnen; Tatjana Heinrich; Wendy-Anne Smith; Susan L Prescott; Patrick G Holt; Peter M Siba; Deborah Lehmann; Anita H J van den Biggelaar
Journal:  Clin Vaccine Immunol       Date:  2009-09-23

7.  Pertussis toxin improves immune responses to a combined pneumococcal antigen and leads to enhanced protection against Streptococcus pneumoniae.

Authors:  Carolina Salcedo-Rivillas; Anne-Sophie Debrie; Eliane Namie Miyaji; Jorge M C Ferreira; Isaías Raw; Camille Locht; Paulo L Ho; Nathalie Mielcarek; Maria Leonor S Oliveira
Journal:  Clin Vaccine Immunol       Date:  2014-05-07

Review 8.  Panel 6: Vaccines.

Authors:  Stephen I Pelton; Melinda M Pettigrew; Stephen J Barenkamp; Fabrice Godfroid; Carlos G Grijalva; Amanda Leach; Janak Patel; Timothy F Murphy; Sanja Selak; Lauren O Bakaletz
Journal:  Otolaryngol Head Neck Surg       Date:  2013-04       Impact factor: 3.497

9.  Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice.

Authors:  Maria Leonor S Oliveira; Eliane N Miyaji; Daniela M Ferreira; Adriana T Moreno; Patricia C D Ferreira; Fernanda A Lima; Fernanda L Santos; Maria Aparecida Sakauchi; Célia S Takata; Hisako G Higashi; Isaías Raw; Flavia S Kubrusly; Paulo L Ho
Journal:  PLoS One       Date:  2010-05-27       Impact factor: 3.240

Review 10.  Potential role for mucosally active vaccines against pneumococcal pneumonia.

Authors:  Kondwani C Jambo; Enoch Sepako; Robert S Heyderman; Stephen B Gordon
Journal:  Trends Microbiol       Date:  2009-12-22       Impact factor: 17.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.